Step 3 (biologic escalation): Anakinra or infliximab
Biomarker-guided therapy
CRP and ferritin normalization target before steroid taper
Serial troponin and BNP to confirm cardiac recovery
Coronary artery z-score normalization on serial echocardiography
Antiplatelet and anticoagulation evidence
Low-dose aspirin: ACR Class I recommendation for coronary involvement
Continue until z-scores normalize (typically 4–8 weeks)
Anticoagulation evidence: wide practice variation, expert consensus
Giant aneurysms (z-score >= 10) require dual antiplatelet or anticoagulation per AHA guidelines
Follow-up monitoring schedule
1–2 weeks: Repeat labs, ECG, echocardiogram
4–6 weeks: Repeat echocardiogram, labs, ECG
4–6 months: Cardiac MRI if initial LVEF < 50%
10–12 months: Echocardiogram if cardiac abnormalities during acute phase
Patient Discharge Instructions
copy discharge instructions
Diagnosis explanation
Your child was diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C)
MIS-C is a rare inflammatory condition that occurs several weeks after COVID-19 infection
It caused inflammation in multiple organs including the heart
Treatment with IVIG and steroids helps control the inflammation
Medications to continue at home
Take all prescribed medications exactly as instructed
Aspirin: low-dose aspirin as directed by your cardiologist — do not stop without guidance
Steroids: take steroid pills as prescribed — do not stop suddenly
Report any new medications or supplements to your doctor before starting
Avoid ibuprofen (Advil, Motrin) unless specifically directed by your doctor
May interact with aspirin or affect platelet function
Activity restrictions
No strenuous physical activity or organized sports until cleared by cardiology
Your child's heart needs time to recover fully
Avoid PE class, competitive sports, and any vigorous activity
Return-to-sports requires a normal echocardiogram and cardiology clearance
Light activity (slow walking, quiet play) is generally acceptable
Follow-up appointments
Cardiology appointment within 1–2 weeks — this is mandatory
Bring all discharge papers and medication list to the appointment
Repeat echocardiogram at 4–6 weeks after discharge
Repeat blood tests 1–2 weeks after discharge as arranged
Return to emergency department immediately if any of the following occur
Recurrent fever > 38.0 C
Could signal return of inflammation or new infection
Chest pain, palpitations, or difficulty breathing
Signs of cardiac involvement
Fainting, dizziness, or inability to exercise without distress
Severe abdominal pain, persistent vomiting, or inability to eat or drink
Extreme lethargy, confusion, or irritability
Skin that looks mottled, very pale, or blue — especially around the mouth or fingertips
Signs of poor blood flow: skin very cold to touch, not urinating normally
COVID-19 vaccination guidance
COVID-19 vaccination reduces the risk of MIS-C in the future
Discuss timing of vaccination with your doctor at follow-up
Typically deferred for 3–6 months after MIS-C recovery
References
Guidelines and key sources
American College of Rheumatology (ACR) Clinical Guidance
Henderson LA, Canna SW, Friedman KG, et al. ACR Clinical Guidance for MIS-C Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatology. 2022
Feleszko W, Okarska-Napierala M, Buddingh EP, et al. Pathogenesis, Immunology, and Immune-Targeted Management of MIS-C/PIMS. Pediatric Allergy and Immunology. 2023
EAACI position paper on cytokine storm and immune dysregulation
Long-term outcome studies
Truong DT, Trachtenberg FL, Hu C, et al. Six-Month Outcomes in the LOMIS Study. JAMA Pediatrics. 2025
Long-term cardiac and functional outcomes
El Rassi C, El Darzi R, Abou Mansour M, Arabi M. MIS-C: Diagnosis, Management, and Outcomes. Open Forum Infectious Diseases. 2026
Global longitudinal strain as early subclinical dysfunction marker
Maddux AB, Berbert L, Young CC, et al. Health Impairments After Hospitalization for Acute COVID-19 or MIS-C. Pediatrics. 2022
Recovery trajectory and residual morbidity
Diagnostic differentiation
Godfred-Cato S, Abrams JY, Balachandran N, et al. Distinguishing MIS-C From COVID-19, Kawasaki Disease and TSS. Pediatric Infectious Disease Journal. 2022
Scoring system performance metrics (AUC 0.87–0.97)
Darby JB, Jackson JM. Kawasaki Disease and MIS-C: An Overview and Comparison. American Family Physician. 2021
Clinical comparison table and differentiating laboratory features
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.